Centogene: Michael Motz
Michael Motz has been appointed as chief commercial officer, pharmaceuticals, of German rare disease diagnostics company Centogene, effective June 1. Most recently, he was entrepreneur in residence at BB Pureos Bioventures in Switzerland. Before that, he held leadership positions at various firms, including Lion Bioscience, Altana Pharma, Sandoz, Roche, and Zealand Pharma. Motz holds a PhD in biochemistry from the Max Planck Institute for Evolutionary Anthropology.